| Date Checked | 2025-12-21 23:23:01 |
|---|
| Graham Number | (PB)nan vs (PE)0.00 |
|---|
| Over / Under Value Percentage | 0.00% vs 0.00% |
|---|
| Dividend Yield | 0.00% |
|---|
| Dividend Date | None |
|---|
| Symbol | SGEN |
|---|
| AssetType | Common Stock |
|---|
| Name | Seagen Inc |
|---|
| Description | Seagen Inc., a biotechnology company, develops and markets cancer treatment therapies in the United States and internationally. The company is headquartered in Bothell, Washington. |
|---|
| CIK | 1060736 |
|---|
| Exchange | NASDAQ |
|---|
| Currency | USD |
|---|
| Country | USA |
|---|
| Sector | LIFE SCIENCES |
|---|
| Industry | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
|---|
| Address | 21823 30TH DRIVE SE, SUITE, BOTHELL, WA, US |
|---|
| FiscalYearEnd | December |
|---|
| LatestQuarter | 2023-06-30 |
|---|
| MarketCapitalization | 38825333000 |
|---|
| EBITDA | -644238976 |
|---|
| PERatio | 0 |
|---|
| PEGRatio | 18.53 |
|---|
| BookValue | 13.96 |
|---|
| DividendPerShare | 0 |
|---|
| EPS | -3.89 |
|---|
| RevenuePerShareTTM | 11.6 |
|---|
| ProfitMargin | -0.336 |
|---|
| OperatingMarginTTM | -0.331 |
|---|
| ReturnOnAssetsTTM | -0.126 |
|---|
| ReturnOnEquityTTM | -0.261 |
|---|
| RevenueTTM | 2162001000 |
|---|
| GrossProfitTTM | 207993000 |
|---|
| DilutedEPSTTM | -3.89 |
|---|
| QuarterlyEarningsGrowthYOY | 5.23 |
|---|
| QuarterlyRevenueGrowthYOY | 0.214 |
|---|
| AnalystTargetPrice | 224.83 |
|---|
| TrailingPE | - |
|---|
| ForwardPE | 909.09 |
|---|
| PriceToSalesRatioTTM | 12.79 |
|---|
| PriceToBookRatio | 8.16 |
|---|
| EVToRevenue | 11.43 |
|---|
| EVToEBITDA | -38.86 |
|---|
| Beta | 0.494 |
|---|
| 52WeekHigh | 210.5 |
|---|
| 52WeekLow | 116.08 |
|---|
| 50DayMovingAverage | 195.34 |
|---|
| 200DayMovingAverage | 173.87 |
|---|
| SharesOutstanding | 187698000 |
|---|
| ExDividendDate | None |
|---|
| dateChecked | 2025-12-21 23:23:01 |
|---|
| fresh | 1 |
|---|